Delveinsight

JULY 21, 2021

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. Multiple Sclerosis (MS).

Pharma Companies 94

Pharma Companies Marketing Insulin Development 94

XTalks

FEBRUARY 21, 2024

Recently, Eli Lilly revealed promising results from a mid-stage trial, indicating that its popular drug, tirzepatide (marketed as Zepbound and Mounjaro for weight loss and diabetes, respectively), may be an effective treatment for the fatty liver disease metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices. That leaves three years for pharma companies to prepare.

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

XTalks

MAY 13, 2021

A recent report by Market Watch, based on data from a survey conducted by Hub Entertainment Research in November 2020, shows that the proportion of US consumers who said they were watching a lot more TV than they did prior to the pandemic remains unchanged since July 2020. And this trend doesn’t seem to be letting up any time soon.

Insulin 104

Insulin Marketing Branding Drugs 104

XTalks

SEPTEMBER 11, 2023

The first ten drugs to undergo Medicare drug price negotiations were chosen based on criteria determined by Medicare, which include that they be sold in pharmacies, not have significant generic competition and have been on the market for at least nine years (13 years for more complex biologics). billion Medicare enrollees who used drug: 3.7

Drugs 108

Drugs Sales Insulin Life Science 108

XTalks

FEBRUARY 14, 2024

On the other hand, Republican senators largely defended the CEOs and the free market. They also blamed pharmacy benefit managers (PBMs), third-party companies that serve as pharma middlemen, who select which drugs receive insurance coverage and charge drug companies rebates and fees for covering them.

Drugs 52

Drugs Insulin Pharmacy Development 52